Answers are grounded in this paper and cite their sources.
A blood biomarker would be advantageous for early identification or screening for Alzheimer's disease (AD). Multiple reports have identified Cell Cycle Dysregulation as a key pathology in AD. Furthermore, it appears likely that this dysfunction is systemic, affecting peripheral blood lymphocytes as well as neurons. The current study built on two prior published reports that demonstrated differences in lymphocyte proliferation activity in lymphocytes between AD and healthy normal (HN) controls. This study reports multivariate analysis of lymphocyte proliferation in response to a mitogenic stimulus to create an algorithm that best separates the two groups. It potentially represents a blood-based biomarker for AD. 140 blood samples were obtained and 125 of the samples passed analytical review (59 AD and 66 controls). Samples were analyzed by a reference laboratory (Becton Dickinson). CD69 (a surface marker of cell cycle activity) was measured on peripheral T, B, and monocyte cells by flow cytometry with and without mitogenic stimulation. Each subject was characterized by multiple measured features that were collected using the LymPro Test methodology. Public and proprietary feature selection algorithms were used to identify optimal feature sets to maximize diagnosis prediction performance using several commonly used machine-learning methods. Prediction performance was compiled using leave-one-out cross-validation measures. Multiple markers were significantly (p<0.05) different in AD subjects compared with HN subjects using univariate models with multiple markers achieving AUCs of 0.657-0.689. Multivariate results indicate that the cross-validated accuracy can be as high as (or even higher than) 80%, especially for methods based on Support Vector Machines approach, even if only 15-25 (optimally selected) LymPro markers are used for the classification. In this analysis, the LymPro Test reports multiple multivariate combinations which discriminate AD from controls with an accuracy of 80% or higher. The blood-based biomarker panel appears to be a robust and reproducible measure of a key pathology of AD and the results corroborate previously published LymPro findings. Accuracy is likely to become more apparent when measured against biomarker defined study subjects. Additional research is planned.
No takes yet. Share an insight, caveat, or question.
Kirby et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: